 Kian Behbakht
Concepts (439)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 40 | 2024 | 407 | 5.390 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 6 | 2023 | 67 | 1.270 |
Why?
| | Endometrial Neoplasms | 10 | 2019 | 151 | 1.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2020 | 1361 | 1.070 |
Why?
| | Drug Resistance, Neoplasm | 15 | 2023 | 638 | 1.040 |
Why?
| | Genital Neoplasms, Female | 6 | 2020 | 73 | 0.980 |
Why?
| | Uterine Cervical Neoplasms | 8 | 2017 | 213 | 0.970 |
Why?
| | Peritoneal Neoplasms | 6 | 2022 | 54 | 0.970 |
Why?
| | Antineoplastic Agents | 10 | 2023 | 1893 | 0.810 |
Why?
| | Hysterectomy | 4 | 2018 | 118 | 0.790 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 5 | 2017 | 40 | 0.700 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1048 | 0.680 |
Why?
| | Cystadenocarcinoma, Serous | 5 | 2022 | 44 | 0.670 |
Why?
| | Gelatin | 2 | 2016 | 36 | 0.650 |
Why?
| | Neoplasms, Glandular and Epithelial | 3 | 2015 | 39 | 0.620 |
Why?
| | Models, Economic | 1 | 2018 | 48 | 0.610 |
Why?
| | Thrombin | 2 | 2016 | 141 | 0.610 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 65 | 0.600 |
Why?
| | Female | 79 | 2024 | 59932 | 0.550 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 465 | 0.550 |
Why?
| | Pelvic Infection | 1 | 2016 | 4 | 0.540 |
Why?
| | Tissue Adhesives | 1 | 2016 | 17 | 0.540 |
Why?
| | Fallopian Tube Neoplasms | 5 | 2019 | 15 | 0.520 |
Why?
| | Cost-Benefit Analysis | 1 | 2018 | 548 | 0.510 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2017 | 59 | 0.510 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2019 | 863 | 0.490 |
Why?
| | Cell Line, Tumor | 18 | 2023 | 2751 | 0.490 |
Why?
| | Women | 1 | 2015 | 51 | 0.480 |
Why?
| | Sirolimus | 2 | 2016 | 192 | 0.470 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2015 | 1200 | 0.410 |
Why?
| | Middle Aged | 46 | 2020 | 27014 | 0.410 |
Why?
| | Vagina | 5 | 2016 | 148 | 0.410 |
Why?
| | Antibodies, Neoplasm | 1 | 2012 | 30 | 0.400 |
Why?
| | Cisplatin | 2 | 2015 | 263 | 0.400 |
Why?
| | Humans | 83 | 2024 | 115613 | 0.390 |
Why?
| | Neoadjuvant Therapy | 4 | 2020 | 301 | 0.360 |
Why?
| | Neoplasm Staging | 14 | 2019 | 1178 | 0.360 |
Why?
| | Claudin-4 | 3 | 2022 | 9 | 0.360 |
Why?
| | Aged | 34 | 2020 | 19255 | 0.350 |
Why?
| | Robotic Surgical Procedures | 3 | 2016 | 88 | 0.350 |
Why?
| | Uterine Neoplasms | 4 | 2019 | 73 | 0.340 |
Why?
| | Pelvic Exenteration | 1 | 2009 | 11 | 0.340 |
Why?
| | Aged, 80 and over | 17 | 2020 | 6419 | 0.340 |
Why?
| | Apoptosis | 8 | 2019 | 2377 | 0.340 |
Why?
| | Leiomyosarcoma | 3 | 2020 | 24 | 0.340 |
Why?
| | Health Personnel | 1 | 2015 | 582 | 0.330 |
Why?
| | Cytoreduction Surgical Procedures | 2 | 2020 | 40 | 0.330 |
Why?
| | Pyrimidines | 3 | 2019 | 376 | 0.330 |
Why?
| | Paclitaxel | 3 | 2019 | 192 | 0.330 |
Why?
| | Phthalazines | 2 | 2019 | 39 | 0.330 |
Why?
| | Receptors, TNF-Related Apoptosis-Inducing Ligand | 3 | 2017 | 26 | 0.330 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2020 | 334 | 0.310 |
Why?
| | Carcinoma, Endometrioid | 3 | 2019 | 47 | 0.310 |
Why?
| | Clinical Competence | 1 | 2015 | 912 | 0.310 |
Why?
| | Caffeine | 1 | 2008 | 58 | 0.300 |
Why?
| | Carbazoles | 1 | 2008 | 80 | 0.300 |
Why?
| | Azepines | 2 | 2019 | 74 | 0.300 |
Why?
| | Postoperative Complications | 6 | 2020 | 2161 | 0.300 |
Why?
| | Papanicolaou Test | 2 | 2004 | 39 | 0.290 |
Why?
| | Vaginal Smears | 2 | 2004 | 48 | 0.290 |
Why?
| | Piperazines | 2 | 2019 | 314 | 0.290 |
Why?
| | Adult | 29 | 2020 | 30726 | 0.280 |
Why?
| | Protein Kinase C | 1 | 2008 | 274 | 0.280 |
Why?
| | Hemostasis, Surgical | 2 | 2016 | 21 | 0.250 |
Why?
| | Adenocarcinoma | 4 | 2015 | 799 | 0.250 |
Why?
| | Laparotomy | 2 | 2015 | 96 | 0.240 |
Why?
| | Urban Health | 1 | 2004 | 75 | 0.240 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2020 | 1147 | 0.240 |
Why?
| | Disease-Free Survival | 7 | 2017 | 621 | 0.240 |
Why?
| | Fallopian Tubes | 1 | 2024 | 29 | 0.230 |
Why?
| | Pyrazoles | 2 | 2020 | 362 | 0.230 |
Why?
| | Genetic Therapy | 2 | 2014 | 260 | 0.220 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2003 | 39 | 0.210 |
Why?
| | Adenocarcinoma, Clear Cell | 2 | 2021 | 14 | 0.200 |
Why?
| | Leiomyoma | 2 | 2019 | 45 | 0.200 |
Why?
| | Healthcare Disparities | 2 | 2018 | 486 | 0.200 |
Why?
| | Prognosis | 8 | 2020 | 3339 | 0.200 |
Why?
| | Piperidines | 2 | 2019 | 163 | 0.190 |
Why?
| | Treatment Outcome | 11 | 2020 | 9159 | 0.190 |
Why?
| | Hospitals, Public | 1 | 2001 | 23 | 0.190 |
Why?
| | BRCA2 Protein | 3 | 2019 | 42 | 0.190 |
Why?
| | Mutation | 5 | 2019 | 3364 | 0.180 |
Why?
| | Hospitals, University | 1 | 2001 | 172 | 0.180 |
Why?
| | Vulvar Neoplasms | 1 | 2020 | 10 | 0.180 |
Why?
| | Cervix Uteri | 3 | 2011 | 44 | 0.180 |
Why?
| | Neoplasms | 4 | 2017 | 2118 | 0.180 |
Why?
| | Epoxy Compounds | 1 | 2020 | 31 | 0.180 |
Why?
| | Cell Movement | 2 | 2016 | 867 | 0.170 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 43 | 0.170 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 14 | 0.170 |
Why?
| | Enoxaparin | 1 | 2020 | 52 | 0.170 |
Why?
| | Receptors, Adiponectin | 1 | 2019 | 14 | 0.170 |
Why?
| | Up-Regulation | 2 | 2020 | 820 | 0.170 |
Why?
| | Vaccines, Conjugate | 1 | 2019 | 60 | 0.170 |
Why?
| | Pyridones | 1 | 2020 | 125 | 0.160 |
Why?
| | Histocompatibility Antigens | 1 | 2019 | 100 | 0.160 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 88 | 0.160 |
Why?
| | Patient Acceptance of Health Care | 1 | 2004 | 683 | 0.160 |
Why?
| | Sequence Analysis, RNA | 2 | 2019 | 391 | 0.160 |
Why?
| | Interleukin-12 | 2 | 2014 | 110 | 0.160 |
Why?
| | Sarcoma | 1 | 2020 | 137 | 0.160 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2019 | 96 | 0.160 |
Why?
| | Lymph Node Excision | 2 | 2020 | 141 | 0.160 |
Why?
| | Breast Neoplasms | 4 | 2019 | 1872 | 0.160 |
Why?
| | Cancer Vaccines | 1 | 2019 | 137 | 0.160 |
Why?
| | Ovariectomy | 2 | 2015 | 117 | 0.160 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 206 | 0.150 |
Why?
| | Cost Savings | 1 | 2018 | 75 | 0.150 |
Why?
| | Oncologists | 1 | 2018 | 31 | 0.150 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2002 | 289 | 0.150 |
Why?
| | Cell Growth Processes | 2 | 2008 | 52 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2008 | 1870 | 0.150 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 431 | 0.150 |
Why?
| | Neoplasm Grading | 4 | 2019 | 244 | 0.150 |
Why?
| | Aurora Kinase A | 1 | 2017 | 51 | 0.150 |
Why?
| | Survival Rate | 5 | 2020 | 1650 | 0.150 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2019 | 181 | 0.150 |
Why?
| | Leukocyte Common Antigens | 1 | 2017 | 76 | 0.140 |
Why?
| | beta Catenin | 1 | 2019 | 220 | 0.140 |
Why?
| | Fatty Acids | 1 | 2020 | 386 | 0.140 |
Why?
| | Risk Factors | 6 | 2016 | 8699 | 0.140 |
Why?
| | Anion Transport Proteins | 1 | 2017 | 8 | 0.140 |
Why?
| | Salpingectomy | 2 | 2015 | 13 | 0.140 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2017 | 31 | 0.140 |
Why?
| | Gestational Trophoblastic Disease | 1 | 2016 | 6 | 0.140 |
Why?
| | Keratins | 1 | 2017 | 176 | 0.140 |
Why?
| | Curettage | 1 | 2016 | 9 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2020 | 234 | 0.140 |
Why?
| | Minority Groups | 1 | 2018 | 230 | 0.140 |
Why?
| | Megestrol Acetate | 1 | 2016 | 2 | 0.140 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2016 | 29 | 0.140 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2017 | 60 | 0.140 |
Why?
| | Neoplasms, Squamous Cell | 1 | 1996 | 5 | 0.130 |
Why?
| | Colony Count, Microbial | 1 | 2016 | 112 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1536 | 0.130 |
Why?
| | Standard of Care | 1 | 2016 | 63 | 0.130 |
Why?
| | Anticoagulants | 1 | 2020 | 549 | 0.130 |
Why?
| | Medroxyprogesterone Acetate | 1 | 2015 | 29 | 0.130 |
Why?
| | Animals | 12 | 2020 | 32102 | 0.130 |
Why?
| | Adenoviridae | 1 | 1996 | 186 | 0.130 |
Why?
| | Brachytherapy | 1 | 2016 | 104 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 348 | 0.130 |
Why?
| | Gynecology | 1 | 2018 | 185 | 0.130 |
Why?
| | Keratin-5 | 1 | 2015 | 46 | 0.130 |
Why?
| | Tretinoin | 1 | 1996 | 124 | 0.130 |
Why?
| | Chemoradiotherapy | 1 | 2016 | 187 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2017 | 930 | 0.120 |
Why?
| | Tamoxifen | 1 | 2016 | 192 | 0.120 |
Why?
| | Combined Modality Therapy | 4 | 2020 | 1127 | 0.120 |
Why?
| | Immunohistochemistry | 3 | 2016 | 1642 | 0.120 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2015 | 139 | 0.120 |
Why?
| | Immunotherapy | 1 | 2018 | 479 | 0.120 |
Why?
| | CA-125 Antigen | 2 | 2008 | 13 | 0.120 |
Why?
| | Abdominal Abscess | 1 | 2014 | 23 | 0.120 |
Why?
| | Surgeons | 1 | 2018 | 238 | 0.120 |
Why?
| | Young Adult | 5 | 2020 | 10487 | 0.120 |
Why?
| | Lipid Metabolism | 1 | 2017 | 449 | 0.120 |
Why?
| | Reoperation | 1 | 2016 | 525 | 0.120 |
Why?
| | Mice, SCID | 2 | 2012 | 321 | 0.120 |
Why?
| | Cytokines | 1 | 2002 | 1853 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 4 | 2020 | 815 | 0.110 |
Why?
| | Glycoproteins | 1 | 2015 | 309 | 0.110 |
Why?
| | Interpersonal Relations | 1 | 2017 | 342 | 0.110 |
Why?
| | Endometrium | 1 | 2014 | 59 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2018 | 576 | 0.110 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2016 | 400 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 1996 | 446 | 0.110 |
Why?
| | Antigens, CD | 1 | 2015 | 442 | 0.110 |
Why?
| | Mice | 8 | 2020 | 15052 | 0.110 |
Why?
| | Models, Biological | 3 | 2019 | 1646 | 0.110 |
Why?
| | Pelvic Neoplasms | 1 | 2013 | 19 | 0.110 |
Why?
| | Plasmids | 1 | 2014 | 345 | 0.110 |
Why?
| | Genes, Tumor Suppressor | 3 | 1998 | 78 | 0.110 |
Why?
| | Escherichia coli | 1 | 2016 | 730 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2012 | 2574 | 0.100 |
Why?
| | Neoplastic Stem Cells | 1 | 2015 | 331 | 0.100 |
Why?
| | Antibody Specificity | 1 | 2012 | 176 | 0.100 |
Why?
| | Cell Division | 2 | 2008 | 759 | 0.100 |
Why?
| | Endocrine Gland Neoplasms | 1 | 2011 | 1 | 0.100 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 187 | 0.100 |
Why?
| | RNA, Small Interfering | 3 | 2020 | 544 | 0.100 |
Why?
| | Drug Synergism | 2 | 2011 | 317 | 0.100 |
Why?
| | Cyclin D1 | 1 | 2011 | 61 | 0.100 |
Why?
| | MicroRNAs | 1 | 2017 | 607 | 0.090 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 40 | 0.090 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2011 | 61 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2019 | 2194 | 0.090 |
Why?
| | DNA | 1 | 2017 | 1356 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 864 | 0.090 |
Why?
| | Transfection | 2 | 2007 | 866 | 0.090 |
Why?
| | Cadherins | 1 | 2011 | 175 | 0.090 |
Why?
| | Neoplasm Invasiveness | 3 | 2016 | 445 | 0.090 |
Why?
| | Inflammation | 1 | 2020 | 2500 | 0.090 |
Why?
| | Lymphoma | 1 | 2011 | 178 | 0.090 |
Why?
| | Age Factors | 5 | 2016 | 2907 | 0.090 |
Why?
| | Adolescent | 5 | 2020 | 17903 | 0.090 |
Why?
| | Skin Transplantation | 1 | 2009 | 58 | 0.080 |
Why?
| | Anastomosis, Surgical | 1 | 2009 | 140 | 0.080 |
Why?
| | Cell Survival | 3 | 2017 | 1024 | 0.080 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2011 | 374 | 0.080 |
Why?
| | Papillomaviridae | 2 | 2002 | 100 | 0.080 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2008 | 28 | 0.080 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2011 | 362 | 0.080 |
Why?
| | G2 Phase | 1 | 2008 | 31 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2019 | 3023 | 0.080 |
Why?
| | Rectum | 1 | 2009 | 151 | 0.080 |
Why?
| | Radiation-Protective Agents | 1 | 2008 | 26 | 0.080 |
Why?
| | Models, Statistical | 1 | 2011 | 606 | 0.070 |
Why?
| | Heterografts | 2 | 2019 | 119 | 0.070 |
Why?
| | Genes, BRCA1 | 2 | 1998 | 33 | 0.070 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 76 | 0.070 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2020 | 704 | 0.070 |
Why?
| | Microsatellite Instability | 2 | 2019 | 32 | 0.070 |
Why?
| | Urinary Bladder | 1 | 2009 | 165 | 0.070 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 344 | 0.070 |
Why?
| | Retrospective Studies | 6 | 2020 | 12608 | 0.070 |
Why?
| | Cysteine | 1 | 2008 | 173 | 0.070 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2019 | 449 | 0.070 |
Why?
| | Length of Stay | 3 | 2015 | 958 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2019 | 1659 | 0.070 |
Why?
| | PTEN Phosphohydrolase | 2 | 2019 | 142 | 0.070 |
Why?
| | Gynecologic Surgical Procedures | 2 | 2020 | 49 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4440 | 0.070 |
Why?
| | Signal Transduction | 4 | 2012 | 4541 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1087 | 0.070 |
Why?
| | Models, Animal | 1 | 2008 | 350 | 0.070 |
Why?
| | Adenosarcoma | 2 | 2005 | 3 | 0.070 |
Why?
| | United States | 5 | 2022 | 12297 | 0.070 |
Why?
| | Indazoles | 2 | 2019 | 58 | 0.060 |
Why?
| | Ovary | 1 | 2007 | 190 | 0.060 |
Why?
| | Cell Cycle | 1 | 2008 | 546 | 0.060 |
Why?
| | Intestinal Neoplasms | 1 | 2005 | 24 | 0.060 |
Why?
| | Colposcopy | 2 | 2003 | 17 | 0.060 |
Why?
| | Neoplasm Proteins | 3 | 1998 | 385 | 0.060 |
Why?
| | Sexual Behavior | 1 | 2009 | 440 | 0.060 |
Why?
| | Disease Progression | 3 | 2019 | 2418 | 0.060 |
Why?
| | Cell Count | 2 | 2015 | 305 | 0.060 |
Why?
| | Germ-Line Mutation | 2 | 1996 | 131 | 0.060 |
Why?
| | Ultraviolet Rays | 1 | 2008 | 372 | 0.060 |
Why?
| | Chicago | 1 | 2004 | 45 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 1996 | 850 | 0.060 |
Why?
| | Transcription Factors | 4 | 2011 | 1528 | 0.060 |
Why?
| | Peptide Fragments | 1 | 2008 | 675 | 0.060 |
Why?
| | Blood Loss, Surgical | 2 | 2015 | 86 | 0.060 |
Why?
| | Antioxidants | 1 | 2008 | 533 | 0.060 |
Why?
| | Survival Analysis | 4 | 2020 | 1219 | 0.060 |
Why?
| | Polymerase Chain Reaction | 3 | 2002 | 1001 | 0.050 |
Why?
| | Activating Transcription Factor 6 | 1 | 2023 | 16 | 0.050 |
Why?
| | Receptors, Estrogen | 2 | 2015 | 372 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2015 | 526 | 0.050 |
Why?
| | Transcription Factor AP-1 | 1 | 2023 | 82 | 0.050 |
Why?
| | Women's Health | 1 | 2004 | 271 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 14 | 0.050 |
Why?
| | Risk Assessment | 3 | 2016 | 2987 | 0.050 |
Why?
| | Gardnerella vaginalis | 1 | 2002 | 2 | 0.050 |
Why?
| | Trichomonas vaginalis | 1 | 2002 | 7 | 0.050 |
Why?
| | Pregnancy | 3 | 2016 | 5550 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2016 | 332 | 0.050 |
Why?
| | Vaginal Neoplasms | 1 | 2001 | 11 | 0.050 |
Why?
| | Gene Expression | 1 | 2007 | 1436 | 0.050 |
Why?
| | Yeasts | 1 | 2002 | 51 | 0.050 |
Why?
| | Vaginal Diseases | 1 | 2001 | 17 | 0.050 |
Why?
| | Databases, Factual | 2 | 2016 | 1138 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2007 | 961 | 0.050 |
Why?
| | Endometriosis | 1 | 2001 | 41 | 0.050 |
Why?
| | DNA, Neoplasm | 2 | 1998 | 157 | 0.050 |
Why?
| | Vulvectomy | 1 | 2020 | 2 | 0.050 |
Why?
| | Prospective Studies | 4 | 2016 | 6264 | 0.050 |
Why?
| | DNA Primers | 1 | 2002 | 514 | 0.050 |
Why?
| | Histiocytoma, Malignant Fibrous | 1 | 2020 | 4 | 0.050 |
Why?
| | Dermatofibrosarcoma | 1 | 2020 | 9 | 0.050 |
Why?
| | Alleles | 3 | 2017 | 794 | 0.050 |
Why?
| | Hospitals, Urban | 1 | 2001 | 129 | 0.050 |
Why?
| | DNA Repair | 1 | 2022 | 190 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 46 | 0.040 |
Why?
| | Liposarcoma | 1 | 2020 | 26 | 0.040 |
Why?
| | Medically Uninsured | 1 | 2001 | 122 | 0.040 |
Why?
| | Anoikis | 1 | 2020 | 31 | 0.040 |
Why?
| | Hemocyanins | 1 | 2019 | 57 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2002 | 299 | 0.040 |
Why?
| | Diagnosis, Differential | 2 | 2019 | 1357 | 0.040 |
Why?
| | Rhabdomyosarcoma | 1 | 2020 | 52 | 0.040 |
Why?
| | DNA Damage | 1 | 2022 | 357 | 0.040 |
Why?
| | Logistic Models | 1 | 2004 | 1856 | 0.040 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2019 | 17 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2002 | 795 | 0.040 |
Why?
| | SEER Program | 1 | 2020 | 195 | 0.040 |
Why?
| | Lymphatic Metastasis | 1 | 2020 | 276 | 0.040 |
Why?
| | Radiotherapy | 1 | 2020 | 177 | 0.040 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2019 | 25 | 0.040 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2019 | 56 | 0.040 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.040 |
Why?
| | DNA Polymerase II | 1 | 2019 | 37 | 0.040 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 84 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 302 | 0.040 |
Why?
| | Chromosomes, Human, Pair 7 | 1 | 1998 | 15 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 99 | 0.040 |
Why?
| | Cytoskeletal Proteins | 1 | 2019 | 145 | 0.040 |
Why?
| | Mitosis | 1 | 2019 | 164 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 1 | 2019 | 174 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2019 | 175 | 0.040 |
Why?
| | Europe | 1 | 2019 | 336 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2002 | 677 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 148 | 0.040 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 1998 | 31 | 0.040 |
Why?
| | Image Cytometry | 1 | 2017 | 5 | 0.040 |
Why?
| | Interleukin-1 | 1 | 2002 | 971 | 0.040 |
Why?
| | Chromosomes, Human, Pair 14 | 1 | 1997 | 16 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1086 | 0.040 |
Why?
| | Indoles | 1 | 2019 | 309 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 924 | 0.030 |
Why?
| | Ganciclovir | 1 | 1996 | 49 | 0.030 |
Why?
| | Chromosome Deletion | 1 | 1997 | 95 | 0.030 |
Why?
| | Cell Differentiation | 2 | 2011 | 1700 | 0.030 |
Why?
| | Time Factors | 2 | 2019 | 6165 | 0.030 |
Why?
| | Health Facility Size | 1 | 2016 | 12 | 0.030 |
Why?
| | Hospitals, Private | 1 | 2016 | 12 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 645 | 0.030 |
Why?
| | Chorionic Gonadotropin | 1 | 2016 | 78 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2019 | 362 | 0.030 |
Why?
| | Cell Separation | 1 | 2017 | 293 | 0.030 |
Why?
| | Ifosfamide | 1 | 1996 | 32 | 0.030 |
Why?
| | AC133 Antigen | 1 | 2015 | 20 | 0.030 |
Why?
| | Cell Line, Transformed | 1 | 1996 | 133 | 0.030 |
Why?
| | Marriage | 1 | 2017 | 106 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 49 | 0.030 |
Why?
| | Hospital Charges | 1 | 1996 | 39 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2016 | 103 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2017 | 223 | 0.030 |
Why?
| | Tumor Burden | 1 | 2016 | 261 | 0.030 |
Why?
| | Caspase 3 | 1 | 2016 | 237 | 0.030 |
Why?
| | Cystadenocarcinoma, Papillary | 1 | 1995 | 5 | 0.030 |
Why?
| | Cell Cycle Proteins | 1 | 2019 | 553 | 0.030 |
Why?
| | Carboplatin | 1 | 1996 | 139 | 0.030 |
Why?
| | Disease Management | 1 | 2019 | 563 | 0.030 |
Why?
| | DNA Mismatch Repair | 1 | 2015 | 37 | 0.030 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2015 | 63 | 0.030 |
Why?
| | Ileus | 1 | 2015 | 10 | 0.030 |
Why?
| | Income | 1 | 2016 | 170 | 0.030 |
Why?
| | Genes, p53 | 1 | 1995 | 62 | 0.030 |
Why?
| | Elective Surgical Procedures | 1 | 2016 | 154 | 0.030 |
Why?
| | Urinary Retention | 1 | 2015 | 19 | 0.030 |
Why?
| | Female Urogenital Diseases | 1 | 2014 | 5 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1718 | 0.030 |
Why?
| | Histones | 1 | 2019 | 540 | 0.030 |
Why?
| | Taxoids | 1 | 2015 | 94 | 0.030 |
Why?
| | Morbidity | 1 | 2015 | 278 | 0.030 |
Why?
| | RNA Interference | 1 | 2016 | 438 | 0.030 |
Why?
| | Receptors, Androgen | 1 | 2015 | 132 | 0.030 |
Why?
| | Intraoperative Complications | 1 | 2015 | 126 | 0.030 |
Why?
| | Multivariate Analysis | 2 | 1996 | 1440 | 0.030 |
Why?
| | Reference Values | 1 | 1996 | 744 | 0.030 |
Why?
| | Bevacizumab | 1 | 2015 | 118 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2016 | 724 | 0.030 |
Why?
| | Blood Volume | 1 | 2014 | 56 | 0.030 |
Why?
| | Point Mutation | 1 | 1995 | 217 | 0.030 |
Why?
| | Bleomycin | 1 | 1996 | 232 | 0.030 |
Why?
| | Infusions, Parenteral | 1 | 2014 | 38 | 0.030 |
Why?
| | Polyethyleneimine | 1 | 2014 | 18 | 0.030 |
Why?
| | Pelvis | 1 | 2015 | 92 | 0.030 |
Why?
| | Deoxycytidine | 1 | 2015 | 140 | 0.030 |
Why?
| | Insurance, Health | 1 | 2016 | 246 | 0.030 |
Why?
| | Hemostatics | 1 | 2014 | 48 | 0.030 |
Why?
| | DNA, Viral | 1 | 1996 | 351 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 286 | 0.030 |
Why?
| | Drainage | 1 | 2014 | 151 | 0.030 |
Why?
| | Receptors, Progesterone | 1 | 2015 | 319 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2018 | 646 | 0.030 |
Why?
| | Anemia | 1 | 2015 | 144 | 0.030 |
Why?
| | Biomarkers | 1 | 2024 | 3468 | 0.030 |
Why?
| | Urban Population | 1 | 2016 | 406 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 588 | 0.030 |
Why?
| | Preoperative Care | 1 | 2015 | 318 | 0.030 |
Why?
| | Patient Readmission | 1 | 2018 | 609 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2015 | 175 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2014 | 148 | 0.030 |
Why?
| | Membrane Proteins | 1 | 2019 | 1024 | 0.030 |
Why?
| | Ultrasonography | 1 | 2016 | 642 | 0.030 |
Why?
| | Polymorphism, Single-Stranded Conformational | 3 | 1998 | 27 | 0.030 |
Why?
| | Rural Population | 1 | 2016 | 448 | 0.030 |
Why?
| | Cholesterol | 1 | 2014 | 369 | 0.030 |
Why?
| | Linear Models | 1 | 1994 | 776 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2017 | 790 | 0.020 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2011 | 23 | 0.020 |
Why?
| | Perioperative Period | 1 | 2011 | 49 | 0.020 |
Why?
| | Analysis of Variance | 1 | 1994 | 1227 | 0.020 |
Why?
| | Comorbidity | 1 | 2016 | 1473 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2011 | 96 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2013 | 201 | 0.020 |
Why?
| | DNA Fragmentation | 1 | 2011 | 47 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2392 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 59 | 0.020 |
Why?
| | Hyperplasia | 1 | 2011 | 166 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2012 | 283 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2015 | 667 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2011 | 235 | 0.020 |
Why?
| | Administration, Oral | 1 | 2012 | 734 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1919 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2011 | 167 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2014 | 431 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 2387 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 576 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 959 | 0.020 |
Why?
| | Patient Discharge | 1 | 2015 | 770 | 0.020 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2008 | 10 | 0.020 |
Why?
| | Injections, Subcutaneous | 1 | 2008 | 137 | 0.020 |
Why?
| | Blotting, Western | 1 | 2011 | 1153 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2011 | 757 | 0.020 |
Why?
| | Placebos | 1 | 2008 | 197 | 0.020 |
Why?
| | Sulfonamides | 1 | 2011 | 447 | 0.020 |
Why?
| | Quality Improvement | 1 | 2015 | 958 | 0.020 |
Why?
| | Mice, Hairless | 1 | 2008 | 74 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2016 | 3580 | 0.020 |
Why?
| | Chromosome Mapping | 2 | 1998 | 489 | 0.020 |
Why?
| | Molecular Sequence Data | 3 | 1996 | 2790 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 4438 | 0.020 |
Why?
| | Genetic Markers | 2 | 1998 | 325 | 0.020 |
Why?
| | Receptors, Cell Surface | 1 | 2008 | 356 | 0.020 |
Why?
| | Frameshift Mutation | 2 | 1996 | 27 | 0.020 |
Why?
| | Gene Deletion | 2 | 1998 | 355 | 0.020 |
Why?
| | Carcinosarcoma | 1 | 2005 | 17 | 0.020 |
Why?
| | Cohort Studies | 1 | 2015 | 4945 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1485 | 0.020 |
Why?
| | Colorado | 1 | 2014 | 4116 | 0.020 |
Why?
| | DNA Mutational Analysis | 2 | 1996 | 372 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2011 | 2578 | 0.010 |
Why?
| | Obesity | 1 | 2016 | 2517 | 0.010 |
Why?
| | Base Sequence | 2 | 1996 | 2114 | 0.010 |
Why?
| | Loss of Heterozygosity | 1 | 1998 | 41 | 0.010 |
Why?
| | Microsatellite Repeats | 1 | 1998 | 137 | 0.010 |
Why?
| | Actuarial Analysis | 1 | 1996 | 21 | 0.010 |
Why?
| | Genes, Neoplasm | 1 | 1995 | 20 | 0.010 |
Why?
| | BRCA1 Protein | 1 | 1995 | 57 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 1998 | 732 | 0.010 |
Why?
| | Age of Onset | 1 | 1996 | 450 | 0.010 |
Why?
| | Introns | 1 | 1995 | 226 | 0.010 |
Why?
| | Exons | 1 | 1995 | 300 | 0.010 |
Why?
| | Male | 1 | 2017 | 55968 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1995 | 2000 | 0.010 |
Why?
|
|
Behbakht's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|